/
We are a developmental stage biopharmaceutical and cryptocurrency company. Our therapeutics focus is on developing novel therapeutics that address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
The business is unprofitable at the operating level (-5936.95% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 0.0% YoY. The question is whether this is cyclical or a structural shift.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$72K
Net Income (TTM)
-$5M
▲ +3.8% YoY
Op. Margin
-6631.16%
▲ +589.5pp YoY
ROIC
-68.95%
▲ +6.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$4M
▼ -21.6% YoY
Net Debt
-$6M
Net Cash Position
Cash & Equiv.
$6M
5Y CAGR: +12.2%
Continue Research